Source: China – South China Morning PostChina’s health authorities have approved clinical trials of two Covid-19 vaccines that use mRNA, potentially adding an option to the nation’s arsenal in its battle against the pandemic’s worst outbreak since 2020. Cansino Biologics and CSPC Pharmaceutical have been approved by the National Medical Products Administration of China (NMPA) to commence trials, according to statements by the two companies. CanSino’s stock price in Hong Kong jumped 6 per cent to HK$133.10 on Monday morning, after the…Read More